• ResMed’s third-quarter fiscal 2026 results showed higher sales of US$1,431.41 million and net income of US$398.73 million, while the company declared a US$0.60 per-share dividend and announced longtime CFO Brett Sandercock’s planned May 2026 retirement with Aaron Bloomer stepping in as his successor.
• Alongside the earnings beat and margin expansion, the appointment of a new CFO with extensive healthcare and global finance experience adds a fresh layer of financial leadership at a time when ResMed is also pursuing acquisitions and ongoing capital returns.
• We’ll now examine how the stronger margins and upcoming CFO transition may influence ResMed’s existing investment narrative and risk profile.

Find 50 companies with promising cash flow potential yet trading below their fair value.

ResMed Investment Narrative Recap

To own ResMed, you need to be comfortable with a sleep and respiratory care business that leans on recurring device and mask demand, margin discipline, and growing digital health tools. The latest Q3 results, with higher revenue, earnings and margins, support that profit-focused story, while the CFO transition looks orderly rather than disruptive. In the near term, the biggest swing factor still appears to be reimbursement and pricing pressure, not this leadership change.

Among the recent announcements, the US$340 million Noctrix acquisition, aimed at restless leg syndrome, matters most here because it sits alongside the CFO handover. As ResMed broadens beyond core sleep apnea, integrating new assets while maintaining its margin progress and capital return program could be a key test for incoming CFO Aaron Bloomer, especially with ongoing share repurchases and a consistent US$0.60 per share dividend.

Yet beneath the strong quarter, investors should also be aware of the risk that reimbursement tightening or pricing pressure could...

ResMed's narrative projects $6.7 billion revenue and $1.9 billion earnings by 2029. This requires 7.6% yearly revenue growth and about a $0.4 billion earnings increase from $1.5 billion today.

Uncover how ResMed's forecasts yield a $288.21 fair value, a 41% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already assuming revenue of about US$6.6 billion and earnings of roughly US$1.8 billion by 2029, which bakes in slower growth and a lower valuation multiple than today; if acquisitions like Noctrix or the new CFO’s capital decisions play out differently, your own view on ResMed’s margin and earnings potential could sit well above or below that more pessimistic path.

Explore 6 other fair value estimates on ResMed - why the stock might be worth as much as 41% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your ResMed research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free ResMed research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ResMed's overall financial health at a glance.

Curious About Other Options?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.